Search

Displaying results 1041 - 1050 of 9323 in total
  1. Drug

    Valproate bismuth

    go.drugbank.com/drugs/DB13910
    Approved

    Valproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Lincomycin

    go.drugbank.com/drugs/DB01627
    ApprovedInvestigationalVet approved

    [A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964.[L33214] … Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium _Streptomyces lincolnensis_ in Lincoln, Nebraska.

  3. Drug

    Chloramphenicol

    go.drugbank.com/drugs/DB00446
    ApprovedInvestigationalVet approvedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this … It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic.

    Products: PALMITATO DE CHLOROMYCETIN
  4. Drug

    Dihydroergocornine

    go.drugbank.com/drugs/DB11273
    Approved

    [A32964] The formation of dihydroergocornine implies the hydrogenation of the double bonds in the lysergic acid. … [T190] It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to [DB01049]

  5. Drug

    Chlorphentermine

    go.drugbank.com/drugs/DB01556
    ApprovedIllicitWithdrawn

    It has properties similar to those of dextroamphetamine. It has been implicated in lipid storage disorders and pulmonary hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1223)

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Soybean oil

    go.drugbank.com/drugs/DB09422
    ApprovedInvestigational

    Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use. … The major component fatty acids are linoleic (48% - 58%), oleic (17% - 30%), palmitic (9% -13%), linolenic (4% - 11%), and stearic (2.5% - 5.0%).

    Mixtures: Olimel 7.6% E, Olimel 4.4% E
  7. Drug

    Artemether

    go.drugbank.com/drugs/DB06697
    ApprovedInvestigational

    </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. … This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.

  8. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    [A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. … [A255582] Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability.

    Products: SARIDINE - E
  9. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    [A222078] The chief surface target of EBOV particles is the GP<sub>1,2</sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high

  10. Drug

    Eltrombopag

    go.drugbank.com/drugs/DB06210
    ApprovedInvestigational

    Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked … ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood.